Table 3. Main studies examining multimodal therapy for colorectal cancer with peritoneal carcinosis.
| Author, year | Study | Level of evidence | Therapy(treatment arm vs control arm) | Number of patients (n) | Median survival (months) or survival rate |
| Verwaal et al. 2003 (15), 2008 (16) | prospective randomized | 1b | SC vs. CRS + HIPEC+SC | 105 | 12 vs. 22 |
| Elias et al. 2009 (17) | retrospective, matched-pair | 3b | SC vs. CRS + HIPEC | 48 | 23 vs. 63 |
| Franko 2010 et al. (18) | retrospective, matched-pair | 3b | SC vs. CRS + EPIC | 105 | 16 vs. 34 |
| Matheme et al. 2004 (19) | historic comparison group | 3b | CRS + EPIC vs. debulking + SC | 18 | 32 vs. 14 |
| Glehen et al. 2004 (20) | Multinational register | 2b | CRS + HIPEC | 506 | 19 |
| Elias et al. 2010 (21) | French register | 4 | CRS + HIPEC + SC | 523 | 30 |
| Cao et al. 2009 (22) | systematic meta-analysis | 2a | CRS + HIPEC + SC | >2000 (47 studies) | 15 to 60 |
| Elias et al. 2010 (13) | retrospective comparative study | 2b | CRS + HIPEC + SC colon vs. rectum | 368 | 5 years: 30% vs. 38% |
| Elias 2004 et al. (e5) | prospective randomized (not completed) | 2b | CRS + SC vs. CRS + EPIC | 35 | 2 years: 60% vs. 60% |
| Esquivel et al. 2007 (6) | consensus statement | 3a | SC + CRS + HIPEC | – | – |
| Glehen et al. 2010 (e6) | retrospective multi-center | 2b | CRS + HIPEC + EPIC | 1106 | 30 |
SC: systemic chemotherapy; EPIC: early post-operative intraperitoneal chemotherapy; CRS: cytoreductive surgery (peritonectomy); HIPEC: hyperthermic intraperitoneal chemotherapy